Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV Faricimab (Vabysmo) in Diabetic Macular Edema with Adaptive Optics Assessment
2023-509829-52-00Phase 4Authorised
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Sep 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of faricimab in diabetic macular edema (DME), sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: Change in best corrected visual acuity (BCVA) from baseline to Month 12 (Week 52). Planned start Sep 2025; status: authorised.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2023-509829-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509829-52-00.